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The predominant p63 isoform, ΔNp63, is a master regulator of
normal epithelial stem cell (SC) maintenance. However, in vivo
evidence of the regulation of cancer stem cell (CSC) properties
by p63 is still limited. Here, we exploit the transgenic MMTV-ErbB2
(v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2)
mouse model of carcinogenesis to dissect the role of p63 in the
regulation of mammary CSC self-renewal and breast tumorigene-
sis. ErbB2 tumor cells enriched for SC-like properties display in-
creased levels of ΔNp63 expression compared with normal
mammary progenitors. Down-regulation of p63 in ErbB2 mammo-
spheres markedly restricts self-renewal and expansion of CSCs, and
this action is fully independent of p53. Furthermore, transplantation
of ErbB2 progenitors expressing shRNAs against p63 into the mam-
mary fat pads of syngeneic mice delays tumor growth in vivo. p63
knockdown in ErbB2 progenitors diminishes the expression of genes
encoding components of the Sonic Hedgehog (Hh) signaling path-
way, a driver of mammary SC self-renewal. Remarkably, p63 regu-
lates the expression of Sonic Hedgehog (Shh), GLI family zinc finger
2 (Gli2), and Patched1 (Ptch1) genes by directly binding to their gene
regulatory regions, and eventually contributes to pathway activa-
tion. Collectively, these studies highlight the importance of p63 in
maintaining the self-renewal potential of mammary CSCs via a pos-
itive modulation of the Hh signaling pathway.
mammary stem cells | p53 family | breast cancer
Deregulation of self-renewal may be a crucial event under-lying tumorigenesis. Cancer stem cells (CSCs) are thought
to use numerous signaling pathways underlying normal SC bio-
logy aberrantly (1). As a result, CSCs acquire unlimited self-
renewal potential and drive tumor growth and metastases. Thus,
unveiling the molecular basis of stem cell (SC) self-renewal may
be extremely relevant in understanding how this process con-
tributes to cancer development.
Emerging evidence intimately links the p53 sister homolog
tumor protein p63 (p63) to SC biology (2–4). The TP63 gene is
expressed as multiple protein isoforms (5). The use of alternative
transcription start sites (TSSs) produces transactivating (TA)
isoforms that contain an N-terminal exon encoding a p53-like
transactivation domain (TAD) and ΔN isoforms partially lacking
this domain. ΔNp63 proteins can directly regulate transcription
due to the presence of alternative TADs (6). Both the TAp63
and ΔNp63 transcripts are differentially spliced at their 3′ ends
to generate proteins with unique C termini designated α, β, and γ
(5), whose biology has not yet been deeply studied.
ΔNp63, the predominant p63 isoform in epithelial tissues, is
indispensable for preserving the self-renewal capacity of SCs in
adult stratified epithelia and glandular structures (2–4). In nor-
mal breast tissue, the expression of ΔNp63 is strictly restricted to
the basal/myoepithelial compartment (7), where SCs are expected
to reside. The requirement for p63 in the morphogenesis of the
mammary gland was originally suggested by the observation
that complete abrogation of TP63 gene function in animal
models causes loss of the mammary epithelium (8, 9). Emerging
evidence is pointing toward a role for p63 in regulating stemness
in the adult mammary gland (3, 10, 11), although the clinical
relevance of p63 as a SC marker in breast cancer remains poorly
understood.
Ectopic expression of ΔNp63 in breast carcinoma cell lines
increases the percentage of CSC-like subpopulations and leads
to augmented cancer cell clonogenicity and tumor xenograft in-
cidence (12). Accordingly, ΔNp63 is overexpressed in the basal-
like subtype of breast cancer (13, 14), in which a specific role for
ΔNp63 in regulating CSC activity has been reported very re-
cently (11). In differentiated mammary tumors, such as luminal-
like breast carcinomas, ΔNp63 expression is instead reduced
during cancer progression (7). In invasive ductal carcinomas,
ΔNp63 positivity is generally restricted to rare tumor cells. Oc-
casional nuclear positivity for ΔNp63 in malignant cells is con-
sistent with a stem/progenitor identity and suggests that ΔNp63
enrichment would confer increased self-renewal potential. Here,
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we demonstrate that ΔNp63 promotes the stemness properties of
luminal-type breast cancer progenitors and identify the Hedgehog
(Hh) signaling pathway as a downstream effector of p63 activity
in mammary CSCs.
Results
Mammary Cancer Progenitors Are Enriched for ΔNp63 Expression. To
dissect the role of p63 in breast CSC self-renewal, we used
transgenic mice expressing mammary gland-targeted ErbB2
(MMTV-ErbB2). Expression of the activated ErbB2 oncogene
in murine mammary epithelium efficiently induces multifocal
luminal-like mammary carcinomas (15). The ErbB2 tumor has
been shown to classify with human luminal-type carcinoma (16,
17), and represents a well-established SC model of mammary
carcinogenesis (15). The expression pattern of p63 in the ErbB2-
derived mammary tumors closely mirrors the expression pattern
of p63 in human ductal carcinomas (7). p63 positivity indeed
diminishes during progression from hyperplasia to invasive
lesions that ultimately display rare immunoreactive tumor cells
(Fig. S1 A–D). Interestingly, we found that a fraction of the p63-
expressing cells were also positive for stem cell antigen 1 (Sca-1)
(Fig. S1E), which identifies a CSC population highly enriched for
tumorigenic capability in this breast cancer model (15). Thus,
p63 positivity in tumor cells is consistent with a stem/progenitor
identity in the ErbB2 tumors.
To examine the expression pattern of p63 in mammary CSCs,
we took advantage of the mammosphere culture system, which
enriches for self-renewing tumorigenic progenitors and mimics
the original tumor upon transplantation into syngeneic mice
(18). The ΔNp63 transcript (Fig. 1A) and protein (Fig. 1B) levels
were consistently increased in ErbB2 mammospheres compared
with their normal counterparts. By contrast, TAp63 expression
was very low or absent in the ErbB2 tumor spheres (Fig. 1 A and
B and Fig. S1 F and H), indicating that ΔNp63 is the pre-
dominant p63 isoform. As shown by Western blot analyses (Fig.
1B and Fig. S1 F and H), the expression pattern of the ΔNp63
isoforms was very heterogeneous in distinct tumor sphere prep-
arations, with the ΔNp63γ variant being the most abundant
isoform. To assess whether ErbB2 CSCs are enriched for p63
expression, we isolated quiescent progenitors on the basis of their
ability to retain the lipophilic fluorescent dye PKH-26 (15, 19).
Immunostaining of PKH-26negative (progenitors) and PKH-26high
(stem) epithelial cells revealed that p63 was preferentially ex-
pressed in the quiescent population (Fig. 1C). As shown in Fig.
1D, the PKH-26high subpopulations displayed augmented levels
of ΔNp63 transcripts compared with the PKH-26negative cells.
TAp63 expression was barely detectable in the PKH-26high cells
(Fig. 1E). These findings reveal that ΔNp63 is the primary p63
isoform expressed in ErbB2 CSCs.
Loss of ΔNp63 Impairs Self-Renewal and Expansion of Mammary
CSCs. Serial sphere-forming capacity represents a valid surro-
gate for assessing CSC self-renewal (18). To test whether ΔNp63
affects the self-renewal potential of mammary CSCs, we trans-
duced ErbB2 secondary mammospheres with lentiviral shRNA
targeting p63 mRNA. Assessment of gene knockdown revealed
that ΔNp63 mRNA (Fig. 2A, Right and Fig. S1G) and protein
(Fig. S1H) levels were down-regulated by ∼80% upon short
hairpin p63 (shp63) delivery. Functional inactivation of ΔNp63
in shp63-transduced ErbB2 progenitors was confirmed by re-
duced transcript levels of its direct target genes (Fig. S1I).
Depletion of p63 caused a significant decrease in the number
of sphere-forming cells during serial passages (Fig. 2A, Left),
demonstrating that the self-renewal capacity of tumor progeni-
tors was impaired in the absence of p63. Furthermore, the size of
shp63 mammospheres was reduced compared with the controls
(Fig. 2B), suggesting that p63 down-regulation may negatively affect
either the frequency of CSCs or their proliferation potential.
To corroborate further the role of ΔNp63 in the regulation of
breast cancer stemness, we performed isoform-specific inactivation
of TAp63 or ΔNp63 in the human HCC1937 breast cancer cell line
that expresses both isoforms at the endogenous level (Fig. S2A).
Specific loss of ΔNp63, but not TAp63 (Fig. S2B), decreased the
ability of HCC1937 cells to form mammospheres (Fig. S2C). Sim-
ilarly, transduction of MCF-7 cells, lacking detectable endogenous
TAp63 mRNA (Fig. S2A), with a pan-p63 shRNA-harboring len-
tivirus significantly reduced their mammosphere-forming efficiency
(Fig. S2 D and E). Taken together, these findings indicate that
ΔNp63, but not TAp63, contributes to sustain mammary CSC ex-
pansion by promoting CSC self-renewal and proliferation.
Because p63 and p53 physically interact (20), ΔNp63 can act in
a dominant negative fashion to inhibit p53 tumor-suppressive
properties. Hence, one potential mechanism by which ΔNp63
may preserve self-renewal is by functionally counteracting p53,
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Fig. 1. Expression pattern of p63 in mammary cancer progenitors.
(A) ΔNp63 and TAp63 mRNA expression levels in wild-type (WT) and ErbB2
(Tum) secondary mammospheres measured by quantitative real-time PCR
(qPCR). TATA box-binding protein (TBP) mRNA levels were used as an in-
ternal normalization control. Data are presented as mean ± SD. Five in-
dependent experiments were performed for each mouse genotype. (B, Left)
Immunoblot (IB) analysis of p63 protein levels in total cellular extracts of
control (WT) and ErbB2 (Tum) mammospheres obtained from three in-
dependent tumors. (B, Right) Densitometric quantification of p63 protein
levels in WT and ErbB2 spheres. Band intensity was normalized against
vinculin. Values are expressed as the ratio of p63/vinculin amount × 100.
(C ) Representative photographs of p63 immunofluorescence staining of
PKH-26high (Left) and PKH-26negative (Right) cells isolated from ErbB2 spheres.
Nuclei were counterstained with DAPI. Green indicates antibody staining,
red indicates PKH fluorescence, and blue indicates DAPI. (Scale bars: 10 μm.)
Transcript levels of ΔNp63 (D) and TAp63 (E) in PKH-26high and PKH-26negative
populations that were FACS-sorted from four independent labeled ErbB2
mammosphere preparations. TBP mRNA levels were used as an internal
normalization control. Data are presented as mean ± SD.
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which crucially controls the replicative properties of mammary
CSCs (15). To test this possibility, we down-regulated p63 in
secondary mammospheres obtained from the mammary gland of
p53 KO mice. We observed that p63 depletion impaired the self-
renewing ability of mammary progenitors (Fig. 2C, Left) and
reduced sphere size (Fig. 2D) even in a p53 null background.
These findings demonstrate that p63 sustains mammary CSC
replicative potential through a p53-independent mechanism.
Notably, down-regulation of p63 expression was maintained
throughout serial replatings in both ErbB2 and p53 null progen-
itors. However, at later passages, we always observed re-expression
of p63 correlating with increased self-renewing potential (e.g., Fig.
2C, Right), indicating that a positive selection reactivated the self-
renewal of CSCs.
Depletion of p63 in ErbB2 Progenitors Attenuates Mammary Tumor
Growth. To assess whether loss of p63 in mammary cancer pro-
genitors may halt ErbB2-driven tumorigenesis, we used p63-
depleted spheres for in vivo transplantation assays. We found that
depletion of p63 markedly suppressed breast cancer growth in
vivo relative to control mice (Fig. 2E). Tumor growth inhibition
was paralleled by decreased frequency of Ki-67–positive nuclei in
shp63 compared with short hairpin scrambled (shSCR) tumors
(Fig. 2 F and G).
To determine whether reactivation of p63 might also occur in
vivo in the shp63-transplanted tumors, we evaluated p63 im-
munoreactivity in tumor sections. Interestingly, we observed that
the percentage of p63-positive cells was comparable in shp63
(0.025% ± 0.02) and control (0.044% ± 0.017) tumors (P = 0.3).
Thus, given the similarity to the mammosphere culture system,
the proliferation of residual p63 proficient cells within the
implanted shp63 cell population might have overtaken the p63
KO during tumor progression.
p63 Regulates the Hh Signaling Pathway in Mammary CSCs. The Hh
signaling pathway is a relevant driver of epithelial SC self-
renewal (21). The Hh signaling cascade is initiated when one of
the three secreted ligands, Sonic Hedgehog (SHH), Desert
Hedgehog, or Indian Hedgehog (IHH), binds and inactivates
the Patched1 (PTCH1) receptor. Upon binding, PTCH1 relieves
its inhibition on Smoothened (SMO), which then activates the
Glioma-associated oncogene homologues 1, 2, and 3 (GLI 1,2,3)
family of transcription factors. The expression levels of Hh target
genes, such as Gli1 and Ptch1, are used as markers of active
canonical Hh signaling (22). The effects of Hh signaling on
mammary SC self-renewal have been ascribed to the transcrip-
tional activation of the SC marker B-cell–specific Moloney mu-
rine leukemia virus Integration site1 (BMI1) (21). Aberrant
regulation of the Hh pathway promotes self-renewal and ex-
pansion of CSCs in several human cancers (21–24).
Several reports demonstrated that in tumor cell lines, the p63
isoforms regulate the transcription of some key players of the
Hh signaling (25, 26). However, the potential contribution of the
p63-Hh cross-talk to breast cancer stemness remains unexplored.
Therefore, we examined whether p63 may sustain mammary CSC
self-renewal through the activation of the Hh pathway. Interest-
ingly, p63 knockdown in ErbB2 progenitors resulted in altered
expression of various Hh signaling components (Fig. 3A). Shh,
Ptch1, Gli2, and Bmi1 transcript levels were reduced in shp63
compared with control mammospheres. Conversely, the expres-
sion of Ihh was up-regulated in shp63 compared with shSCR
spheres. This finding is in accordance with the observation that Ihh
is targeted by ΔNp63 for transcriptional repression in quiescent
normal mammary SCs (3). The expression of other Hh molecules,
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Fig. 2. p63 supports mammary CSC self-renewal and mammary tumor
growth. (A, Left) Semilogarithmic plotting of cumulative sphere number
(±SD of quadruplicates) during in vitro passaging of control scrambled
(shSCR) and p63-depleted (shp63) ErbB2 spheres. Data are representative of
four individual experiments. GR, growth rate. (A, Right) ΔNp63 mRNA levels
were measured at passages 1 and 5. TBP expression was used as an internal
control. (B, Upper) Representative phase-contrast photographs of shSCR and
shp63 ErbB2 spheres. (Scale bars: 100 μm.) (B, Lower) Average mammosphere
size during serial replatings of shSCR and shp63 ErbB2 progenitors, calcu-
lated as cell number per sphere ± SD (P < 0.01). (C, Left) Cumulative sphere
number (±SD of quadruplicates) of shSCR and shp63 mammospheres
obtained from the p53 null (−/−) mammary epithelium. (C, Right) Data are
representative of three individual experiments. Relative ΔNp63 mRNA levels
were measured at passages 1 and 5. (D, Upper) Representative photographs
of control and p63-depleted p53−/− spheres. (Scale bars: 100 μm.) (D, Lower)
Average size (±SD) of p53−/− mammospheres expressing shRNA-targeting
p63 relative to scrambled controls (P < 0.01). (E) Growth rate of secondary
breast tumors arising from transplantation of shSCR or shp63 ErbB2 epithelial
cells into the mammary fat pad of female syngeneic recipients. Ten weeks
postinjection, all animals were killed and tumor volume was quantified. Data
represent mean ± SEM (P < 0.05). (F) Representative Ki-67 staining of shSCR
and shp63 transplanted tumors. (Scale bars: Upper, 100 μm; Lower, 50 μm).
(G) Proliferative activity of shSCR and shp63 transplanted tumors assessed as
the Ki-67 labeling index. Error bars represent mean ± SD. Data were generated
from three animals from each experimental group. *P < 0.01.
A
B C
Fig. 3. p63 activates the Hh signaling pathway in mammary CSCs. (A) Shh,
Ptch1, Gli2, Bmi1, and Ihh gene expression was quantified by qPCR using four
independent preparations of RNA obtained from shSCR and shp63 ErbB2
mammospheres. Data are expressed as mean ± SD and are normalized to TBP
expression. *P < 0.001; **P < 0.003; ***P < 0.005. Tumors from shSCR- and
shp63-transplanted mice were analyzed using SHH (B) and GLI2 (C) immuno-
histochemistry. Representative images from three independent tumors for
each experimental group are presented. (Scale bars: 100 μm.)
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such GLI1 and SMO, was not significantly affected by p63 loss. In
addition, histological examination of p63 shRNA-expressing tu-
mor transplants revealed in vivo down-regulation of SHH (Fig.
3B) and GLI2 (Fig. 3C) compared with control tumors.
Mammary SC self-renewal is regulated by a number of addi-
tional signaling pathways, including Notch, TGF-β, and Wnt/
β-catenin, which are aberrantly activated in CSCs (27). In-
terestingly, some of the components of these pathways are under
the transcriptional control of p63. For instance, p63 regulates the
expression of several molecules of the Notch pathway (28, 29).
Moreover, in basal-like breast tumors, ΔNp63 regulates CSC
properties through the induction of Fzd7 expression and sub-
sequent activation of the Wnt/β-catenin pathway (11). To assess
whether p63 also promotes SC activity through the modulation
of these two pathways, we measured the expression levels of
Notch receptors and Notch target genes, as well as the expres-
sion levels of Fzd7, in p63-depleted ErbB2 mammospheres. We
found that silencing of p63 does not significantly affect the ex-
pression of any of these genes (Fig. S3), demonstrating that
neither Notch nor Wnt/β-catenin is a relevant signaling mediator
of p63 stemness activity in our model system. This observation
may be in line with a divergent cluster-of-cluster-assignment evo-
lution of basal vs. luminal breast cancers (14).
p63 Directly Regulates the Transcription of Hh Signaling Components.
We then asked whether p63 directly binds to the regulatory
regions of some of the Hh components. Genome-wide profiling
of p63-binding sites by ChIP-sequencing analysis of human cells
(30) (Fig. S4 A–C) and mouse cells (31) (Fig. S4G) revealed
peaks of p63 binding to regions encompassing or within the Shh,
Gli2, and Ptch1 loci.
To validate the direct interaction of ΔNp63 with the regula-
tory regions of these genes, we performed ChIP experiments in
breast cancer cells and demonstrated binding of endogenous
ΔNp63 to genomic sites located in proximity to or within the
Shh, Gli2, and Ptch1 loci (Fig. 4A). To characterize the binding
capabilities of p63 to the regulatory regions of these genes fur-
ther, we performed ChIP assays in MCF-7 cells overexpressing
TAp63 or ΔNp63. We found that both isoforms are able to oc-
cupy binding sites encompassing or within the Shh (Fig. S4D),
Gli2 (Fig. S4E), and Ptch1 (Fig. S4F) genes.
Remarkably, ChIP assays in a mouse mammary epithelial cell
line revealed that ΔNp63 specifically binds to a predicted p63 re-
sponsive element within a genomic region encompassing the murine
Shh locus (−30 kb from the TSS; Fig. S4H). These findings highlight
the notion that downstream effectors of p63 in mammary CSC
regulation are conserved between humans and mice.
To study the transcriptional regulation of Shh, Gli2, and Ptch1
by p63, we generated luciferase reporter constructs encompass-
ing the p63-binding regions within these genes. Cotransfection of
the Shh, Gli2, and Ptch1 reporters with the ΔNp63 isoforms in-
creased their basal transactivation levels (Fig. 4B and Fig. S4I).
In accordance with the report by Caserta et al. (25), we found that
the TAp63 isoforms were also able to transactivate the Shh pro-
moter (Fig. S4J). The ΔNp63 isoforms activated the reporter con-
structs to different extents, reflecting their distinct transactivating
properties (32). The p63β- and p63γ-isoforms are generally more
transcriptionally active in vitro than the α-proteins, which possess
a C-terminal autoinhibitory domain reducing their activity. Sim-
ilarly, we found that overexpression of ΔNp63 isoforms in the
MCF-7 breast cancer cells determined different levels of in-
duction of Shh and Gli2 mRNA (Fig. 4C).
To validate the Hh signaling as a downstream effector of p63
in mammary CSC regulation, we assessed the effect of the SMO
inhibitor cyclopamine (CP) on the sphere-forming efficiency of
p63-depleted breast cancer cells. Fig. 4D shows that although the
addition of CP reduced the ability of control cells to form
spheres, it failed to inhibit the sphere formation potential of
tumor cells significantly further upon p63 down-regulation (Fig.
S4K). Taken together, these findings demonstrate that Shh, Gli2,
and Ptch1 are direct transcriptional target genes of p63 in mammary
cells, and that p63 loss diminished the self-renewal potential of
breast CSCs by attenuating Hh activation.
To validate the role of Hh signaling in breast cancer stemness,
we compared the expression levels of Hh transcriptional targets
between WT and ErbB2 mammospheres. ErbB2 progenitors
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Fig. 4. Shh, Gli2, and Ptch1 are direct p63 target genes. (A) Specific binding of
p63 to the regulatory regions of Shh (Left), Gli2 (Middle), and Ptch1 (Right)
genes. ChIP assays were performed in humanMCF-7 breast carcinoma cells using
H129 anti-p63 antibody and control IgG. p63 binds to one regulatory region
within the Shh (+22 kb from the TSS) and Ptch1 (39 kb downstream of the TSS)
genes, and to three regulatory regions (+47, +151 and +191 kb from the TSS,
denoted as #1, #2, and #3) of the Gli2 locus. (B) Luciferase reporter assays of Shh
(Left), Gli2 (Middle), and Ptch1 (Right) regulatory regions. The reporter vectors
were cotransfected with ΔNp63-expressing plasmids into the p53 null human
H1299 cell line. Cellular lysates were either assayed for luciferase activity or an-
alyzed by IB (Insets). Data are presented as mean ± SD and are representative of
three independent experiments. (C) qPCR was performed to analyze the tran-
script levels of Shh (Left) and Gli2 (Middle) quantitatively in MCF-7 cells trans-
fected with constructs expressing the ΔNp63 isoforms. (Right) Protein extracts
were subjected to IB for p63 and β-actin detection. (D) Effect of CP on the sphere-
forming efficiency (SFE) of control and p63-depleted HCC1937 cells. Cells were
transfected with control, pan-p63, and ΔNp63 siRNA oligos and then plated for
the mammosphere-forming assay in the presence of 300 nM CP or the inactive
CP analog tomatidine (Tom). *P < 0.05. (E) RT-qPCR analysis of Hh transcriptional
targets in normal (WT) and ErbB2 (Tum) mammospheres. Seven independent
preparations of RNA for each genotype were analyzed. (F) qPCR analysis of Bmi1
and p63 mRNA in human mammospheres obtained from normal breast tissue
[control (ctrl)] and primary mammary tumors (Patient). (G) Effect of Hh antag-
onists on the self-renewal of mammary CSCs. Primary spheres were dissociated
and cultured with CP or Tom for 7 d. Data are expressed as mean ± SD and are
representative of four independent experiments. *P < 0.05; **P < 0.01.
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displayed increased Ptch1 and Bmi1 transcript levels (Fig. 4E),
indicating augmented activation of the Hh pathway in tumors
compared with normal progenitors. Similarly, CSCs isolated
from primary human breast tumors expressed higher levels of
Bmi1 mRNA relative to normal progenitors obtained from re-
ductive mammoplasties (Fig. 4F, Left). Consistent with the data
obtained for the ErbB2 spheres (Fig. 1A), we found that the
expression of p63 was more elevated in cancer than in normal
mammary progenitors (Fig. 4F, Right).
We next demonstrated that pharmacological blockade of the
Hh pathway by treatment of tumor spheres with CP led to
a dose-dependent reduction of ErbB2 mammosphere-forming
efficiency (Fig. 4G). Similar to other tumor types, collectively,
these findings demonstrate that Hh function contributes to the
maintenance of the self-renewing capacity of mammary CSCs.
To validate the relationship between the expression of p63 and
the Hh signaling pathway in the clinical setting, we analyzed the
Molecular Taxonomy of Breast Cancer International Consortium
(METABRIC) dataset (33), a collection of 2,000 clinically anno-
tated primary breast cancer specimens. We found a strong positive
correlation between p63 and Gli2 mRNA levels (Fig. S5A). The
values of Pearson correlation between p63 and Gli2 are presented
in Fig. S5D. Comparable results for p63 and Gli2 expression were
obtained using the cBioPortal for Cancer Genomics database (www.
cbioportal.org/). As previously reported (11), our analysis of the
METABRIC dataset confirmed that expression of p63 is also sig-
nificantly correlated with expression of Fzd7 in patients with breast
cancer, at least when using one of two distinct probes (Fig. S5 B–D).
Discussion
p63, a major epithelial transcription factor, is crucial for main-
tenance of the regenerative capacity of several ectoderm-derived
tissues, including the mammary gland (2–4). Our data highlight
a role for ΔNp63 in promoting self-renewal and expansion of
ErbB2 progenitors. Notably, we observed that the ability of
ΔNp63 to sustain the self-replicative potential of mammary
CSCs does not require p53. The observation that ΔΝp63 does
not act through the inhibition of p53 suggests that p63 directly
mediates transcriptional responses that confer SC properties.
Our findings demonstrate that ΔNp63 is the predominant
isoform expressed in ErbB2 progenitors, whereas TAp63 var-
iants are detectable only in a minority of mouse mammosphere
samples, and at very low levels. ΔNp63α-, β-, and γ-isoforms are
all expressed in ErbB2 progenitors, although to varying extent,
likely reflecting the interindividual variability across mice. The
expression levels of ΔNp63 in epithelial stem/progenitor cells
correlate with their proliferating capacity (2). In the normal
mammary gland, the stem and progenitor cell subpopulations
display segregated expression of ΔNp63 and TAp63, respectively
(3). The proposed model for differential TP63 promoter use
implies that the exit of SCs from the quiescent state and elabo-
ration of mammary progenitors require the switch-off of ΔNp63
expression. In our model system, WT mammospheres express
similar levels of ΔNp63 and TAp63, likely because spheres are
composed of heterogeneous populations of progenitors exhibit-
ing various degrees of maturation. Conversely, ErbB2 mammo-
spheres and isolated CSCs are enriched for ΔNp63 expression,
suggesting that aberrant levels of ΔNp63 may lead to de-
regulation of CSC replicative properties and expansion of the
progenitor pool. Indeed, silencing the expression of ΔNp63 in
ErbB2 mammospheres and in breast cancer cell lines remarkably
reduced their number, size, and replating efficiency. Collectively,
our data prove that ΔNp63, but not TAp63, positively regulates
mammary SC activity, corroborating previous reports (11).
Consistent with a diminished self-renewing capacity, in vivo
transplantation of p63-depleted mammospheres delayed breast
tumor growth compared with control progenitors. In shp63
mammosphere cultures, we observed a partial reactivation of p63
over time that correlated with increased self-renewal. Similarly,
re-expression of p63 in transplants during tumor growth might
have attenuated the effect of p63 KO on ErbB2-driven carci-
nogenesis. Indeed, a delay in tumor onset was observed in mice
injected with spheres transduced with p63 shRNA lentiviruses
compared with their control counterparts, although the effects
did not achieve statistical significance.
To date, the molecular mechanisms underlying breast CSC
frequency and maintenance remain poorly understood. To gain
insight into the transcriptional programs downstream of p63 in the
regulation of mammary cancer stemness, we examined the en-
dogenous mRNA expression levels of several components of the
Hh signaling pathway in p63-depleted progenitors. We found that
p63 down-regulation leads to reduced expression of Shh, Ptch1,
and Gli2. Hence, because SHH signals GLI transcription factors
via ligation of the PTCH receptors, p63 seems to affect the Hh
pathway at different hierarchical levels of the signaling cascade,
namely, the ligand, its receptor, and downstream transcription
factors. As a result, the SC marker Bmi1, an Hh target gene, is
down-regulated upon p63 depletion. Together, these findings
imply that p63 activates the Hh pathway and likely influences
stemness, at least in part, through the induction of Bmi1, which is
indispensable for cell survival and self-renewal of SCs (21, 34). To
examine further how p63 interferes with the Hh pathway, we
asked whether p63 might directly control the transcription of some
of the Hh molecules. We found that p63 interacts with the regu-
latory regions of the Shh, Gli2, and Ptch1 genes, thus inducing
their expression and promoting Hh pathway activation.
Although the regulation of Shh and Gli2 expression by TAp63
and ΔNp63, respectively, has already been reported in tumor cell
lines (25, 26), we now demonstrate that several components of
the Hh pathway are transcriptionally controlled by ΔNp63 in
mammary CSCs. Additionally, we identified Ptch1 as a pre-
viously unidentified direct target of p63 transcriptional activity.
Using p53 KO mammospheres, we showed that p63 does not
require p53 to regulate mammary cancer stemness. However, the
existence of interplay between p53 and the Hh pathway has been
reported (35, 36). p53 was shown to repress tumorigenic Hh
signals by negatively regulating the activity of GLI1 (35, 37).
Interestingly, constitutively activated mutants of SMO, as well
as elevated levels of GLI1 and GLI2, inhibit p53 accumulation
by promoting binding of p53 to Mdm2 and its subsequent
ubiquitylation (38). Accordingly, given that ΔNp63 induces Gli2
expression, it is possible that cross-talk between the p53 family
members and the Hh pathway would ultimately contribute to
enhance CSC self-renewal.
We also considered the possibility that p63 might interfere
with additional signaling pathways implicated in SC self-renewal,
such as Notch and Wnt/β-catenin. However, the expression of
Notch receptors and Fzd7 was not significantly influenced by p63
silencing in our model system or by ectopic expression of ΔNp63
in the luminal-subtype MCF-7 breast cancer cell line. Fzd7-
dependent enhancement of Wnt signaling by ΔNp63 may pref-
erentially occur in basal-like mammary tumors (11). Consistently,
aberrant Wnt/β-catenin pathway activation is enriched in human
basal-like, rather than luminal-like, mammary tumors (39–41).
Constitutive Hh signaling activation, as a result of overex-
pression of Hh components, including SHH, PTCH1, GLI1, and
GLI2, has been linked to breast tumorigenesis and invasiveness
(42, 43). The mechanisms underlying the up-regulation of Hh
components in tumors are still poorly characterized. Promoter
hypomethylation and deregulation of transcription factors have
been associated with the overexpression of Hh molecules. De-
regulation of ΔNp63 expression in mammary CSCs might result
in aberrant activation of the Hh pathway, augmented SC self-
renewal, and expansion of cancer progenitors.
Overall, our findings contribute to the identification of path-
ways downstream of p63 involved in epithelial CSC regulation
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and shed light on the molecular mechanisms underlying aberrant
activation of Hh signaling in breast cancer.
Materials and Methods
Mice. FVB-Tg (MMTV-Erbb2) transgenic and p53 KO mice on a C57/BL6J
background were previously described (15). Corresponding WT strains were
purchased from Harlan Laboratories. Mice were bred and maintained in
pathogen-free rooms under barrier conditions. All mouse experiments were
performed according to local ethics committee (Ethics Committees of the
University of Tor Vergata and of the European Institute of Oncology) reg-
ulation and were approved by the Italian Ministry of Health.
Mammosphere Cultures. Mammary cells were freshly isolated from mammary
glands of WT and p53 KO mice or from tumors of ErbB2 mice, as previously
described (15). Each WT mammosphere preparation was obtained from pooling
mammary glands from n = 20 mice. For ErbB2 and p53 KO mammosphere
preparation, a single tumor or mammary gland obtained from n = 1 animal was
processed. At each passage, mammospheres were mechanically dissociated and
replated at 20,000 cells per milliliter. For serial passage experiments, 5,000 cells
from mechanically disaggregated mammospheres were plated in quadruplicate.
After 7 d, newly formed mammospheres were counted.
PKH-26 Assay. Freshly isolated mammary epithelial cells were resuspended in
PBS and incubated with a 2× PKH-26 dye (Sigma) solution (1:250) for 5 min,
blocked with 1% BSA, washed twice, and then plated to obtain primary and
secondary mammospheres. Single-cell suspensions from secondary mam-
mospheres were FACS-sorted with a FACS Vantage SE flow cytometer
(Becton Dickinson).
Statistical Analyses. Statistical evaluation was determined using a two-tailed
t test, and values were expressed as mean ± SD (or SEM). Differences were
considered statistically significant at P < 0.05. Details of all other methods
are described in SI Materials and Methods.
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SI Materials and Methods
Cell Culture. MCF-7, HCC1937, H1299, and Normal Murine
Mammary gland (NMuMG) cells were cultured in DMEM
(Lonza), 2 mM glutamine, 100 U/mL penicillin and 100 μg/mL
streptomycin, and 10% FBS. Medium of NMuMG was addi-
tionally supplemented with 10 μg/mL insulin.
Real-Time PCR. Total RNA was isolated (RNeasy Micro Kit;
Qiagen) and reverse-transcribed using QuantiTect Reverse
Transcription (Qiagen). RT-quantitative PCR (qPCR) reactions
were performed using the 7500 Fast Real-Time PCR System
apparatus (Applied Biosystems), with TaqMan Gene Expression
Master Mix (Applied Biosystems). For RT-qPCR, the following
primers were used: mTAp63 (forward), CACCCAGACAAGC-
GAGTTC; mTAp63 (reverse), TCCAGAAAATCCCAGATA-
TGC; mΔNp63 (forward), CTGGCAAAACCCTGGAAG; mΔNp63
(reverse), CAACATGTTAGCAGTGAGACTGG; hTAp63
(forward), 5′-TCAGAAGATGGTGCGACAAAC-3′; hTAp63
(reverse), 5′-GTTCAGGAGCCCCAGGTTCG-3′; hΔNp63 (for-
ward), 5′-GAAGAAAGGACAGCAGCATTG-3′; hΔNp63 (re-
verse), 5′-GGGACTGGTGGACGAGGAG-3′; hShh (forward),
5′-GGAGCGGACAGGCTGATG-3′; hShh (reverse), 5′-GAT-
GGCCAAAGCGTTCAACT-3′; hGli2 (forward), 5′-CAGCT-
GCGCAAACACATGA-3′; and hGli2 (reverse), 5′-TTGAGT-
GACTTGAGCTTCTCCTTCT-3′. Predesigned real-time PCR
assays were purchased (Applied Biosystems) for the following
genes: mShh (Mm00436528_m1), mIhh (Mm00439613_m1),
mPtch1 (Mm00436026_m1), mGli2 (Mm01293117_m1), mBmi-1
(Mm00776122_gh), mJunB (Mm00492781_s1), mEGF-R
(Mm00433023_m1), mNotch1 (mm00435245_m1), mNotch3
(Mm00435270_m1), mHes1 (mm00468601_m1), mHey2
(Mm00469280_m1), mFzd7 (Mm00433409_s1), and hBmi1
(hs00180411_m1). All of the experiments were run in triplicate,
and the results were normalized to TBP or 18S expression.
Western Blot Analysis. Cells were lysed in radioimmunopreci-
pitation assay buffer supplemented with protease and phospha-
tase inhibitors. Total cell extracts were subjected to SDS/PAGE,
followed by immunoblotting with mouse monoclonal anti-p63
Ab4 (clone 4A4, 1:400; NeoMarkers) and mouse monoclonal
antivinculin (1:1,000; Sigma) antibodies. Densitometric analysis
of the blots was performed using ImageLab software, version 5.0
(BioRad).
Immunohistochemical Staining. Tissues were surgically removed,
fixed with 4% (wt/vol) paraformaldehyde, paraffin-embedded,
and sectioned. Sections were deparaffinized by xylene and re-
hydrated in graded alcohol. Slides were preincubated with
blocking solution [2% (wt/vol) BSA, 2% (vol/vol) normal goat
serum, and 0.02% Tween 20 in TBS] and then stained with
primary antibodies overnight at 4 °C. Slides were incubated with
secondary antibody (HRP rabbit or mouse antibody; DAKO
EnVision System) for 30 min at room temperature. After
washing, sections were incubated in peroxidase substrate solu-
tion (DAB; DAKO), rinsed in water, and counterstained with
hematoxylin. Immunohistochemistry was applied to localize
anti-p63 (clone 4A4, 1:500; Neomarkers), anti–Ki-67 (clone
B56, 1:1,000; BD Biosciences), anti-SHH (clone H160, 1:200;
Santa Cruz Biotechnology), and anti-GLI2 (clone ab7195, 1:200;
Abcam). For quantification of Ki-67 staining, randomly taken
images (at least five fields per animal) were captured from tissue
sections and processed with ImageJ software (National Institutes
of Health).
Immunofluorescence. Immunofluorescence analysis of ErbB2 tu-
mor sections was performed as previously described (1). Briefly,
tissues were fixed in 4% (wt/vol) paraformaldehyde and em-
bedded in paraffin. Sections were deparaffinized and rehydrated
stepwise in alcohol/distilled water. Microwave-assisted antigen
retrieval was performed in 0.01 M sodium citrate (pH 6.0) for
three cycles of 5 min (300 W), followed by cooling at 50 °C.
Nonspecific antigens were blocked by incubation in 5% (vol/vol)
goat serum in PBS for 1 h in a humidified atmosphere at room
temperature. Subsequently, sections were incubated overnight
with primary antibodies. Sections were then washed three times
with PBS and incubated for 1 h with anti-mouse Cy3 antibody or
anti-rat Alexa-488 antibody (Molecular Probes; Invitrogen).
After two washes in PBS, the tissue sections were counterstained
with DAPI to highlight nuclei.
Transplantation Assays. For transplantation experiments, p63 ex-
pression was silenced in two independent mammosphere prep-
arations. shSCR or shp63 mammospheres were dissociated,
pelleted, and resuspended in PBS. One hundred thousand
mammary cells were injected into the inguinal mammary fat pad
of 3-wk-old syngeneic female mice. For each independent
preparation, shSCR and shp63 mammary cancer progenitors
were used for injecting a total of n = 2 and n = 5 mice, respectively.
The occurrence of palpable tumors was monitored twice a week.
Due to ethical regulatory issues at our institute, all mice were
euthanized, 10 wk after transplantation, when the tumor mass in
the first control (shSCR) animal reached ∼2 cm in diameter.
Tumors were then measured and processed for analyses. One
mouse in each experimental group (shSCR and shp63) was ex-
cluded from the analysis because these mice died from causes
other than cancer.
ChIP Assays. ChIP experiments were performed using the
MAGnify Chromatin Immunoprecipitation System (Invitrogen).
Briefly, cells were cross-linked for 10 min at room temperature
with 1% (wt/vol) formaldehyde (Merck). The cross-linking re-
action was stopped by addition of 125 mM glycine for 5 min,
followed by a washing step with PBS. The pellet was lysed and
sonicated using a sonicator (Bioruptor UCD-200; Diagenode),
shearing the chromatin into 500- to 1,000-bp fragments. The
chromatin extract was incubated with Dynabeads Protein A/G
coupled, respectively, to 10 μg of rabbit anti-p63 antibody (Clone
H-129; Santa Cruz Biotechnology) or rabbit anti-HA tag anti-
body (ab9110; Abcam) and rabbit IgG (Invitrogen) as negative
controls at 4 °C with rotation for 2 h. The immunocomplexes
were washed and treated with proteinase K (20 mg/mL) at 55 °C
for 15 min to reverse the cross-linking. DNA was purified with
the DNA purification magnetic beads, dissolved in elution
buffer, and used for PCR analysis. The following oligos were
used: hShh promoter: forward 5′-CCTTCCCATGTGGCCTC-
TT-3′, reverse 5′-ACAGGAGAGGCTGCGTTTAGG-3′; mShh
promoter: forward 5′-TTGCCCAGCCTCCAAAACCTTC-3′, re-
verse 5′-AGACCTACCAACTTCATCACCAGTG-3′; peak 1
hGli2 promoter: forward 5′-CCTGGGCATGCAGAGGAA-3′,
reverse 5′-CTTCATGATGAGGTAGGAGGTAGCT-3′; peak 2
hGli2 promoter: forward 5′-CACTTCCTTCCCTTTCTCTCACA-3′,
reverse, 3′-GGAGGAGAAAGGAGGGCATCT-3′; peak 5 hGli2
promoter: forward 5′-CGTTTTCACTTCTCTTGGGTATGTG-3′,
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reverse 5′-ATGGAGCAGCGTTTTTGGAA-3′; and hPtch1 pro-
moter: forward 5′-GCCGGGTGGCATTTGTC-3′, reverse 5′-CT-
GGGCCTGTGCTCATTGAT-3′. PCR products were analyzed
by electrophoresis on agarose gels.
Luciferase Reporter Assay. PGL3-basic luciferase reporter vectors
were constructed by amplification of the genomic regions con-
taining the p63-binding sites (+22, +191, and +30 kb from the
TSS for Shh, Gli2, and Ptch1 genes, respectively). The following
primers were used for the Shh, Gli2, and Ptch1 genomic regions,
respectively: forward, 5′-CTAGCTAGCTTGCCCAGCCTCC-
AAAACCTTC-3′; reverse, 5′-CCGCTCGAGAGACCTACCA-
ACTTCATCACCAGTGC-3′; forward, 5′-CTAGCTAGCCTG-
TATGGATTTGCCTGTTCTGG-3′; reverse, 5′-CCGCTCGA-
GTCATTCATTGTGGGTGGAAAGG3-3′; forward, 5′-CTG-
GGCCTGTGCTCATTGAT-3′; and reverse, 5′-CCGCTCGA-
GCAGCTCGCCTATGCCTGTC-3′. The amplified regions were
cloned within NheI and XhoI sites in PGL3 promoter. H1299 cells
were transfected with 300 ng of luciferase reporters and 2 ng of
internal control plasmid TK-Renilla reporter (Promega), in the
absence or presence of 900 ng of cDNAs expressing p63 isoforms
using Effectene (Qiagen). Twenty hours after transfection, cells
were lysed and luciferase activity was measured by using the Dual
Luciferase Reporter Assay System protocol (Promega) according
to the manufacturer’s instructions. The pRL-TK vector was in-
cluded to normalize transfection efficiency, and reporter basal
luciferase activity was normalized as 1.
RNAi-Mediated Gene Silencing. The siRNA duplexes were synthe-
sized by Sigma-Aldrich. For p63 knockdown, siRNA sequences
were as follows: 5′-GCGACAAACAAGAUUGAGA-3′ for TAp63
no. 1, 5′-CGACAAACAAGAUUGAGAUU-3′ for TAp63 no. 2,
and 5′-GCAGCAUUGAUCAAUCUUA-3′ for ΔNp63. Trans-
fection was performed using Lipofectamine RNAiMAX (Life
Technologies) according to the manufacturer’s protocol and
optimized for a six-well plate. In brief, 30 nmol of siRNA was
mixed with 5 μL of Lipofectamine RNAiMAX in 0.4 mL of
OptiMEM medium (Invitrogen). The mixture was added to the
cells. Twenty-four hours after transfection, the cell culture me-
dium was replaced with fresh medium.
Lentiviral-Mediated Transduction of shRNAs. For murine progeni-
tors, disaggregated spheres were plated at a density of 50,000 cells
per milliliter in standard conditions. Lentiviral particles (multi-
plicity of infection = 1) bearing shSCR and shp63 (Santa Cruz
Biotechnology) were added to the culture medium, along with
8 μg/mL polybrene. After two infection cycles, mammospheres
were collected, dissociated to single cells, and incubated with
1 μg/mL puromycin for 3 d. Human breast cancer cell lines were
transduced with SMARTchoice lentiviral shRNA particles (clone
SH-003330-02-10; Thermo Scientific) targeting p63 mRNA. Cells at
density of 1 × 105 cells per well were seeded in a six-well plate, and
24 h, they were infected with virus suspension containing-medium
supplemented with 8 μg/mL polybrene. Forty-eight hours after
infection, cells were selected in medium containing 1 μg/mL
puromycin.
Sphere-Forming Efficiency Assay. For analysis of sphere formation,
following transfection with Lipofectamine RNAiMAX or lenti-
viral infection, single-cell suspensions of breast cancer cells were
plated in 24-well culture plates covered with poly-2-hydroxyethyl-
methacrylate (Sigma) to prevent cell attachment, at a density of
1,000–2,000 cells per milliliter, in serum-free DMEM supple-
mented with 5 μg/mL insulin, 0.5 μg/mL hydrocortisone, 2%
(vol/vol) B27 (Invitrogen), 20 ng/mL EGF and bFGF (BD Bio-
sciences), and 4 μg/mL heparin (Sigma). The medium was made
semisolid by the addition of 1% (vol/vol) methylcellulose to
prevent cell aggregation. The number of spheres for each well
was evaluated 7 d after seeding, and sphere formation rate was
counted. Sphere-forming efficiency was calculated as the number
of spheres formed divided by the original number of single cells
seeded and expressed as a percentage.
Bioinformatics Analysis. METABRIC gene expression data
(mRNA) have been used (2). The Pearson correlation coefficient
was computed as a measure of correlation between mRNA profiles
of two genes [p63 and a partner (i.e., Gli2, Fzd7)]. We used these
data as the observed distribution for correlation coefficients be-
tween p63 and a gene in the METABRIC dataset and estimated
the P value of correlation between p63 and a partner gene using
this distribution. In this case, the P value is an observed probability
of randomly selecting a gene that would correlate with p63 on the
same or a better level.
1. Candi E, et al. (2007) DeltaNp63 regulates thymic development through enhanced
expression of FgfR2 and Jag2. Proc Natl Acad Sci USA 104(29):11999–12004.
2. Curtis C, et al.; METABRIC Group (2012) The genomic and transcriptomic architecture
of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346–352.
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Fig. S1. (A–D) Immunohistochemical analysis of p63 expression in the mouse mammary gland and breast lesions occurring during ErbB2-driven carcinogenesis.
(A) In the normal murine mammary gland, p63 is expressed in the basal/myoepithelial cells. (B) Hyperplastic benign lesions retain a continuous peripheral rim of
myoepithelial cells expressing p63. (C) Discontinuous p63 immunoreactivity is present in the peripheral rim of myoepithelial cells in in situ ductal carcinomas.
(D) Invasive ductal carcinomas show p63 immunoreactivity in a rare fraction of neoplastic cells. (Scale bars: A–D, 100 μm.) (E) Representative immunofluo-
rescence staining of sections of ErbB2 invasive ductal carcinomas analyzed for p63 and stem cell antigen 1 (Sca-1) expression. Arrows indicate cells immuno-
reactive for either Sca-1 (red), p63 (green), or both antigens (red/green). (Scale bars: 2 μm.) (F) Immunoblot (IB) analysis of p63 protein levels in total cellular
extracts of control (WT) and ErbB2 (Tum) mammospheres. Vinculin amounts were used as a loading control. (G and H) Knockdown of p63 in ErbB2 mam-
mospheres upon lentiviral-mediated delivery of shRNAs against p63. (G) ΔNp63 mRNA levels were measured in shSCR and shp63 tumor spheres. RNA levels
were normalized to TATA box-binding protein (TBP) mRNA amounts. Error bars represent mean ± SD of six independent experiments. (H) IB showing p63
down-regulation in ErbB2 spheres expressing shRNAs against p63. (I) Transcript levels of EGF receptor (EGF-R) and JunB in shSCR and shp63 ErbB2 spheres.
mRNA levels were normalized to TBP mRNA amounts. Data are presented as mean ± SD.
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Fig. S2. Loss of ΔNp63 decreases the sphere-forming efficiency (SFE) of breast cancer cells. (A) RT-qPCR analysis of total cDNA from HCC1937 and MCF7 cells
using primers specific to TAp63 (black bars) or ΔNp63 (white bars) isoforms. Expression of p63 isoforms was normalized to the ubiquitin amounts. Results are
mean ± SD. (B) ΔNp63 (Left) and TAp63 (Right) isoform-specific RT-qPCR analysis of HCC1937 after treatment with nonsilencing control siRNA (Scr) or siRNA
oligos specific to the ΔNp63 or to TAp63 isoforms (TAP#1 and TAP#2). Expression of p63 isoforms was normalized to the ubiquitin amounts. Results are mean ±
SD. (C) Averages of the SFE of HCC1937 cells upon siRNA-mediated knockdown of TAp63 and ΔNp63 isoforms. HCC1937 cells were transfected with control
siRNA, ΔNp63, or two TAp63 siRNAs for 48 h and then plated for the mammosphere-forming assay. The SFE was calculated as the percentage of the number of
spheres per plated cell at every passage. Values represent the mean of three independent experiments ± SD (*P = 0.016). (D) ΔNp63 mRNA levels in MCF-7 cells
transduced with control (Scr) and pan-p63 shRNA (shp63) lentiviral constructs. Expression of p63 was normalized to the ubiquitin mRNA levels. Results are
mean ± SD. (E) SFE ± SD of MCF-7 cells infected with Scr and shp63 lentiviral shRNA constructs. The SFE was calculated as above. (**P < 0.05).
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Fig. S3. Expression levels of components of the Notch and Wnt/β-catenin pathways in p63-depleted ErbB2 progenitors. (A–E) Notch1, Notch3, Hes1, Hey, and
Fzd7 transcript level expression was quantified by RT-qPCR using four independent preparations of RNA obtained from shSCR and shp63 ErbB2 mammo-
spheres. Data are expressed as mean ± SD and are normalized to TBP expression. The resultant values for each group are normalized to the expression levels of
the target gene in the shSCR controls.
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Fig. S4. p63 DNA-binding profiles in the Shh (A), Gli2 (B), and Ptch1 (C) loci, obtained in human primary epidermal keratinocytes by ChIP-sequencing (ChIP-
seq) using 4A4 and H129 anti-p63 antibodies in two normal human primary keratinocyte cell lines (K1 and K2) (1). The majority of p63 peaks are located within
genes or in regions upstream of core promoters. (D–F) ChIP analysis of TAp63 and ΔNp63 occupancy at the regulatory regions of Shh (Left), Gli2 (Middle), and
Ptch1 (Right) genes. ChIP assays were performed in human MCF-7 breast carcinoma cells transfected with HA-TAp63α– or HA-ΔNp63α–expressing vectors using
rabbit anti-HA antibody and control IgG. PCR validation was performed using primers spanning the p63-binding sites located within the genomic regions
identified by ChIP-seq assays (1). (G) Identification of p63-binding regions in the Shh mouse locus. The position of the p63-binding site in a genomic region
upstream of the mouse Shh core promoter (−30 kb from the TSS) was obtained by ChIP-seq using 4A4 anti-p63 antibody in murine endodermal END2 cells (2).
(H) ChIP assays were carried out in the mouse mammary epithelial NMuMG cell line following overexpression of ΔNp63α using the H129 anti-p63 antibody. The
results confirm specific binding of p63 to the putative p63-binding site identified by ChIP-seq analysis. (I) Luciferase reporter construct encompassing the p63-
binding region within the mouse Shh (mShh) locus was efficiently induced by ectopic expression of murine ΔNp63α and ΔNp63γ isoforms in H1299. (J) H1299
cells were transfected with a pGL3-Luc reporter plasmid containing the p63-binding site within the human Shh (hShh) locus, along with the TAp63 isoforms.
Luciferase assays were carried out 24 h posttransfection using a dual-luciferase reporter assay system. Relative luciferase units were normalized to transfection
efficiency by cotransfecting the pRL-TK vector. Data are presented as mean ± SD and are representative of two independent experiments. (Inset) Protein
extracts were prepared in parallel and subjected to IB for p63 and β-actin detection. (K) RT-qPCR analysis of ΔNp63 mRNA levels in HCC1937 cells after
treatment with nonsilencing control (Scr), pan-p63, and ΔNp63 siRNA oligos. Expression of p63 isoforms was normalized to the ubiquitin amounts. Results are
mean ± SD.
1. Kouwenhoven EN, et al. (2010) Genome-wide profiling of p63 DNA-binding sites identifies an element that regulates gene expression during limb development in the 7q21 SHFM1
locus. PLoS Genet 6(8):e1001065.
2. Wolchinsky Z, et al. (2014) Angiomodulin is required for cardiogenesis of embryonic stem cells and is maintained by a feedback loop network of p63 and Activin-A. Stem Cell Res 12(1):
49–59.
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Fig. S5. p63 expression positively correlates with Gli2 expression in human patients with breast cancer. Association between p63 and Gli2 (A) and Fzd7
(B and C) mRNA levels in breast tumors from the METABRIC dataset (∼2,000 samples). The expression rank (Expr Rank, y axis) reflects the relative expression
level between p63 and Gli2 or Fzd7. The Pearson correlation coefficient was computed as a measure of correlation between mRNA profiles of two genes.
(D) Pearson correlation coefficient and P values are indicated.
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